No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MRK241227P150000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest150.00Strike Price0.00Turnover237.09%IV-50.83%PremiumDec 27, 2024Expiry Date50.55Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9880Delta0.0020Gamma1.97Leverage Ratio-0.0500Theta-0.0046Rho-1.94Eff Leverage0.0023Vega
Intraday
- 5D
- Daily
No Data
News
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Boeing and 6 More Contrarian Stocks for 2025
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025 -- Barrons.com
Express News | Merck & Co. will cease production of the medication for treating bacterial infections.
Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website